Wide Resection versus Curettage with Adjuvant Therapy for Giant Cell Tumour of Bone
Purpose To determine the association between type of surgery (wide resection versus curettage with adjuvant therapy) and outcome in patients with giant cell tumour (GCT) of bone. Methods Records of 30 male and 52 female consecutive patients aged 10 to 62 years who underwent wide resection (n=57) or...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2016-08-01
|
Series: | Journal of Orthopaedic Surgery |
Online Access: | https://doi.org/10.1177/1602400221 |
id |
doaj-072de79640154cdaa7ecac80da310226 |
---|---|
record_format |
Article |
spelling |
doaj-072de79640154cdaa7ecac80da3102262020-11-25T03:16:58ZengSAGE PublishingJournal of Orthopaedic Surgery2309-49902016-08-012410.1177/1602400221Wide Resection versus Curettage with Adjuvant Therapy for Giant Cell Tumour of BoneAchmad Fauzi KamalEdi Leonardo SimbolonYogi PrabowoErrol Untung HutagalungPurpose To determine the association between type of surgery (wide resection versus curettage with adjuvant therapy) and outcome in patients with giant cell tumour (GCT) of bone. Methods Records of 30 male and 52 female consecutive patients aged 10 to 62 years who underwent wide resection (n=57) or curettage with adjuvant therapy (n=25) for primary GCT of bone were reviewed. The surgical decision was based on patient age, tumour location, functional demand, and patient preference. The median tumour size was 8.5 cm. Tumours were classified as stage 1 (n=4), stage 2 (n=60), and stage 3 (n=18), and 25%, 68.3%, and 83.3% of them were treated with wide resection, respectively. Functional outcome was assessed using the Musculoskeletal Tumor Society (MSTS) score; the maximum score was 30. Results The wide resection and curettage with adjuvant therapy groups were comparable in terms of patient age, gender, tumour size, location, symptoms, tumour stage, type of biopsy, and MSTS score. The MSTS score was excellent in 50.2% of patients, good in 38.7% of patients, and fair and poor in the remaining patients. The MSTS score was not associated with tumour stage or type of surgery. Four patients in the wide resection group had metastasis to the lung. They also had lower haemoglobin level (10.6 vs. 12.7 g/dl, p=0.020) and higher percentage of stage-3 tumour (100% vs. 17.9%, p=0.001) but had no recurrence (0% vs. 6.4%, p=0.774), compared with those without metastatsis. All died from massive haemoptysis and respiratory failure. Eight patients died; their haemoglobin level was lower than that of patients who were still living (11.2 vs. 12.7 g/dl, p=0.032). Mortality was associated with metastasis (100% vs 5.2%, p<0.001) but not recurrence or complication. Two patients in each group had recurrence; recurrence was not associated with type of surgery. Conclusion There was no association between type of surgery and tumour recurrence, metastasis, or outcome. Curettage with adjuvant therapy was more commonly performed for stage 1 and 2 tumours, whereas wide resection was more for stage 3 tumours. Metastasis was associated with stage 3 tumour and mortality but not recurrence.https://doi.org/10.1177/1602400221 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Achmad Fauzi Kamal Edi Leonardo Simbolon Yogi Prabowo Errol Untung Hutagalung |
spellingShingle |
Achmad Fauzi Kamal Edi Leonardo Simbolon Yogi Prabowo Errol Untung Hutagalung Wide Resection versus Curettage with Adjuvant Therapy for Giant Cell Tumour of Bone Journal of Orthopaedic Surgery |
author_facet |
Achmad Fauzi Kamal Edi Leonardo Simbolon Yogi Prabowo Errol Untung Hutagalung |
author_sort |
Achmad Fauzi Kamal |
title |
Wide Resection versus Curettage with Adjuvant Therapy for Giant Cell Tumour of Bone |
title_short |
Wide Resection versus Curettage with Adjuvant Therapy for Giant Cell Tumour of Bone |
title_full |
Wide Resection versus Curettage with Adjuvant Therapy for Giant Cell Tumour of Bone |
title_fullStr |
Wide Resection versus Curettage with Adjuvant Therapy for Giant Cell Tumour of Bone |
title_full_unstemmed |
Wide Resection versus Curettage with Adjuvant Therapy for Giant Cell Tumour of Bone |
title_sort |
wide resection versus curettage with adjuvant therapy for giant cell tumour of bone |
publisher |
SAGE Publishing |
series |
Journal of Orthopaedic Surgery |
issn |
2309-4990 |
publishDate |
2016-08-01 |
description |
Purpose To determine the association between type of surgery (wide resection versus curettage with adjuvant therapy) and outcome in patients with giant cell tumour (GCT) of bone. Methods Records of 30 male and 52 female consecutive patients aged 10 to 62 years who underwent wide resection (n=57) or curettage with adjuvant therapy (n=25) for primary GCT of bone were reviewed. The surgical decision was based on patient age, tumour location, functional demand, and patient preference. The median tumour size was 8.5 cm. Tumours were classified as stage 1 (n=4), stage 2 (n=60), and stage 3 (n=18), and 25%, 68.3%, and 83.3% of them were treated with wide resection, respectively. Functional outcome was assessed using the Musculoskeletal Tumor Society (MSTS) score; the maximum score was 30. Results The wide resection and curettage with adjuvant therapy groups were comparable in terms of patient age, gender, tumour size, location, symptoms, tumour stage, type of biopsy, and MSTS score. The MSTS score was excellent in 50.2% of patients, good in 38.7% of patients, and fair and poor in the remaining patients. The MSTS score was not associated with tumour stage or type of surgery. Four patients in the wide resection group had metastasis to the lung. They also had lower haemoglobin level (10.6 vs. 12.7 g/dl, p=0.020) and higher percentage of stage-3 tumour (100% vs. 17.9%, p=0.001) but had no recurrence (0% vs. 6.4%, p=0.774), compared with those without metastatsis. All died from massive haemoptysis and respiratory failure. Eight patients died; their haemoglobin level was lower than that of patients who were still living (11.2 vs. 12.7 g/dl, p=0.032). Mortality was associated with metastasis (100% vs 5.2%, p<0.001) but not recurrence or complication. Two patients in each group had recurrence; recurrence was not associated with type of surgery. Conclusion There was no association between type of surgery and tumour recurrence, metastasis, or outcome. Curettage with adjuvant therapy was more commonly performed for stage 1 and 2 tumours, whereas wide resection was more for stage 3 tumours. Metastasis was associated with stage 3 tumour and mortality but not recurrence. |
url |
https://doi.org/10.1177/1602400221 |
work_keys_str_mv |
AT achmadfauzikamal wideresectionversuscurettagewithadjuvanttherapyforgiantcelltumourofbone AT edileonardosimbolon wideresectionversuscurettagewithadjuvanttherapyforgiantcelltumourofbone AT yogiprabowo wideresectionversuscurettagewithadjuvanttherapyforgiantcelltumourofbone AT erroluntunghutagalung wideresectionversuscurettagewithadjuvanttherapyforgiantcelltumourofbone |
_version_ |
1724633920056590336 |